Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma

Summary

This expanded access protocol will allow access to treatment with L-MTP-PE for people with osteosarcoma. L-MTP-PE is an investigational drug that has not been approved by the FDA to treat any condition, including osteosarcoma. L-MTP-PE works by activating certain types of white blood cells, and these active white blood cells help the immune system kill cancer cells.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications